ETON Stock Overview
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.
Eton Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.04|
|52 Week High||US$4.78|
|52 Week Low||US$1.95|
|1 Month Change||21.12%|
|3 Month Change||33.83%|
|1 Year Change||-24.57%|
|3 Year Change||-49.59%|
|5 Year Change||n/a|
|Change since IPO||-51.36%|
Recent News & Updates
Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrousSep 13
Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' StoryAug 14
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging HigherApr 15
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt SafelyOct 14
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their EstimatesAug 18
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The CornerMay 15
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?Apr 05
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?Mar 01
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To ProfitJan 07
Do Insiders Own Lots Of Shares In Eton Pharmaceuticals, Inc. (NASDAQ:ETON)?Jul 06
|ETON||US Pharmaceuticals||US Market|
Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: ETON underperformed the US Market which returned -20.6% over the past year.
|ETON Average Weekly Movement||9.9%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ETON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ETON's weekly volatility (10%) has been stable over the past year.
About the Company
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis.
Eton Pharmaceuticals, Inc. Fundamentals Summary
|ETON fundamental statistics|
Is ETON overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ETON income statement (TTM)|
|Cost of Revenue||US$4.96m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.35|
|Net Profit Margin||-47.19%|
How did ETON perform over the long term?See historical performance and comparison